CONMED Financial Statements (CNMD)
|
|
|
|
Report date
|
|
|
22.02.2022 |
21.02.2023 |
28.02.2024 |
18.02.2025 |
17.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 011 |
1 045 |
1 245 |
1 307 |
1 374 |
|
1 372 |
|
Operating Income, bln rub |
|
|
109.7 |
70.1 |
120.6 |
200.3 |
141.1 |
|
153.4 |
|
EBITDA, bln rub |
? |
|
179.3 |
7.80 |
192.5 |
272.2 |
193.5 |
|
211.4 |
|
Net profit, bln rub |
? |
|
62.5 |
-80.6 |
64.5 |
132.4 |
47.1 |
|
54.8 |
|
|
OCF, bln rub |
? |
|
111.8 |
33.4 |
125.3 |
167.0 |
170.7 |
|
142.6 |
|
CAPEX, bln rub |
? |
|
14.9 |
21.8 |
19.0 |
13.1 |
19.8 |
|
18.9 |
|
FCF, bln rub |
? |
|
96.9 |
11.6 |
106.3 |
153.9 |
150.9 |
|
123.7 |
|
Dividend payout, bln rub
|
|
|
23.3 |
24.0 |
24.5 |
24.7 |
24.7 |
|
18.6 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
37.2% |
0.00% |
38.0% |
18.6% |
52.6% |
|
33.9% |
|
|
OPEX, bln rub |
|
|
458.3 |
501.2 |
555.6 |
532.7 |
584.2 |
|
581.8 |
|
Cost of production, bln rub |
|
|
442.6 |
474.2 |
568.5 |
574.0 |
649.1 |
|
636.9 |
|
R&D, bln rub |
|
|
43.6 |
47.2 |
52.6 |
54.4 |
55.9 |
|
59.3 |
|
Interest expenses, bln rub |
|
|
35.5 |
28.9 |
39.8 |
37.3 |
31.1 |
|
29.9 |
|
|
Assets, bln rub |
|
|
1 766 |
2 298 |
2 300 |
2 306 |
2 326 |
|
2 315 |
|
Net Assets, bln rub |
? |
|
785.4 |
745.5 |
834.2 |
962.7 |
1 033 |
|
1 018 |
|
Debt, bln rub |
|
|
684.7 |
1 055 |
991.3 |
905.8 |
834.9 |
|
860.9 |
|
Cash, bln rub |
|
|
20.8 |
28.9 |
24.3 |
24.5 |
40.8 |
|
35.0 |
|
Net debt, bln rub |
|
|
663.8 |
1 026 |
967.0 |
881.3 |
794.1 |
|
825.8 |
|
|
Ordinary share price, rub |
|
|
141.8 |
88.6 |
109.5 |
68.4 |
40.6 |
|
35.4 |
|
Number of ordinary shares, mln |
|
|
29.2 |
30.0 |
30.7 |
30.8 |
31.0 |
|
30.6 |
|
|
Market cap, bln rub |
|
|
4 134 |
2 663 |
3 358 |
2 111 |
1 260 |
|
1 082 |
|
EV, bln rub |
? |
|
4 798 |
3 689 |
4 325 |
2 992 |
2 054 |
|
1 907 |
|
Book value, bln rub |
|
|
-303 |
-752 |
-622 |
-460 |
-356 |
|
-363 |
|
|
EPS, rub |
? |
|
2.14 |
-2.68 |
2.10 |
4.29 |
1.52 |
|
1.79 |
|
FCF/share, rub |
|
|
3.32 |
0.39 |
3.47 |
4.99 |
4.86 |
|
4.04 |
|
BV/share, rub |
|
|
-10.4 |
-25.0 |
-20.3 |
-14.9 |
-11.5 |
|
-11.9 |
|
|
EBITDA margin, % |
? |
|
17.7% |
0.75% |
15.5% |
20.8% |
14.1% |
|
15.4% |
|
Net margin, % |
? |
|
6.19% |
-7.71% |
5.18% |
10.1% |
3.42% |
|
4.00% |
|
FCF yield, % |
? |
|
2.34% |
0.43% |
3.17% |
7.29% |
12.0% |
|
11.4% |
|
ROE, % |
? |
|
7.96% |
-10.8% |
7.73% |
13.8% |
4.55% |
|
5.39% |
|
ROA, % |
? |
|
3.54% |
-3.51% |
2.80% |
5.74% |
2.02% |
|
2.37% |
|
|
P/E |
? |
|
66.1 |
-33.0 |
52.1 |
15.9 |
26.8 |
|
19.7 |
|
P/FCF |
|
|
42.7 |
229.9 |
31.6 |
13.7 |
8.35 |
|
8.74 |
|
P/S |
? |
|
4.09 |
2.55 |
2.70 |
1.62 |
0.92 |
|
0.79 |
|
P/BV |
? |
|
-13.6 |
-3.54 |
-5.40 |
-4.59 |
-3.54 |
|
-2.98 |
|
EV/EBITDA |
? |
|
26.8 |
473.0 |
22.5 |
11.0 |
10.6 |
|
9.02 |
|
Debt/EBITDA |
|
|
3.70 |
131.6 |
5.02 |
3.24 |
4.10 |
|
3.91 |
|
|
R&D/CAPEX, % |
|
|
293.1% |
216.4% |
276.4% |
416.0% |
282.2% |
|
313.3% |
|
|
CAPEX/Revenue, % |
|
|
1.47% |
2.08% |
1.53% |
1.00% |
1.44% |
|
1.38% |
|
| CONMED shareholders |
